OliX Pharmaceuticals Inc. announced that the Company has received approval from the Alfred Human Research Ethics Committee (HREC) to conduct a Phase 1 clinical trial of drug candidate OLX75016 (the candidate of OLX702A) for the treatment of non-alcohol steatohepatitis (NASH). This randomized, double-blind, placebo-controlled, single and multiple ascending dose study will assess the safety and tolerability of OLX75016 in healthy volunteers. OliX Pharmaceuticals is developing OLX75016 as a novel therapeutic in treating NASH accompanied by liver fibrosis and managing weight.

The Company has secured positive results from a preclinical non-human primates (NHP) study on the efficacy of OLX75016. OLX75016 administered together with a glucagon-like peptide-1 (GLP-1) receptor agonist (semaglutide) demonstrated additional weight-loss effects, mitigated the weight-rebound effect shown upon termination of semaglutide, lowered total body fat mass, and reduced abdominal girth.